Today: 21 May 2026
Bank of America stock: Trump’s 10% card-rate cap and India probe hang over earnings week
10 January 2026
2 mins read

Bank of America stock: Trump’s 10% card-rate cap and India probe hang over earnings week

New York, Jan 10, 2026, 11:13 ET — Market closed

Bank of America shares ended lower on Friday after President Donald Trump called for a one-year cap on credit card interest rates at 10% starting Jan. 20, a proposal that banking trade groups warned could squeeze credit availability. Bank of America (BAC.N) closed down 0.7% at $55.85, after trading between $55.79 and $56.60. “When companies can’t price the risk properly, they’ll just reduce credit lines,” Annex Wealth Management chief economic strategist Brian Jacobsen wrote in an email. reuters.com

The policy headline lands as investors brace for a run of bank earnings and fresh inflation data, both central to the outlook for rates and loan growth. JPMorgan Chase reports on Tuesday, with Bank of America and Citigroup among those due later in the week, while Tuesday’s December Consumer Price Index could steer expectations for the Federal Reserve’s next move. “The banks are going to be telling you something that is going to be pretty important because they’re on the front lines,” Natixis Investment Managers portfolio manager Jack Janasiewicz said. reuters.com

Bank of America is set to report fourth-quarter results on Wednesday, Jan. 14, with the release due around 6:45 a.m. ET and a conference call at 8:30 a.m. ET, the bank said. Traders will look for commentary on net interest income — the spread between what a lender earns on loans and pays out on deposits — and on credit costs in cards and other consumer books.

A separate regulatory issue is also in play. India’s markets regulator has accused a Bank of America business of violating insider-trading rules and breaching internal “Chinese walls” — information barriers meant to keep deal details from spreading inside a bank — in a 2024 share sale, a notice reviewed by Reuters showed. Bank of America has filed an application with the regulator to settle the charges without admitting guilt, a source with direct knowledge of the matter told Reuters. “This case looks less like classic insider trading and more like an internal-controls failure,” said Sumit Agrawal, senior partner at Regstreet Law. reuters.com

On the balance sheet side, Bank of America said it will redeem on Jan. 20 all $3 billion of its 5.080% fixed/floating-rate senior notes due January 2027 at par, plus accrued interest. Fixed/floating notes pay a fixed coupon before switching to a floating rate tied to a benchmark.

The credit card proposal is not law, and Trump offered no details on how a cap would be enforced. Even so, it puts a bright light on an area that feeds earnings at big consumer lenders, including Bank of America, JPMorgan, Citigroup, Capital One and American Express.

With earnings days away, investors are likely to keep it simple. They will watch whether card delinquencies and charge-offs are creeping higher, and whether the bank is building loan-loss reserves faster than expected.

Bank of America’s markets and investment-banking businesses also matter more when volatility picks up. A solid print there can offset pressure in traditional lending if funding costs stay sticky or rate cuts start to bite into loan yields.

Technically, the stock is stuck in a tight band near $56. Friday’s low near $55.80 is the first level traders tend to cite, while $56.60 sits as the most obvious near-term lid after the last session’s high.

But there are clean ways this can go wrong. If the credit-card cap gains traction in Congress, banks could tighten underwriting quickly, and the market may have to reprice card-heavy lenders. A hotter CPI print could also push yields up and shift the debate back to how much — or how little — the Fed can cut in 2026.

The next catalysts are close: December CPI on Tuesday, Jan. 13, followed by Bank of America’s results on Wednesday, Jan. 14, before the opening bell.

Stock Market Today

  • Q1 Earnings Analysis: Pegasystems Lags, Appian Leads Automation Software Stocks
    May 20, 2026, 8:03 PM EDT. As Q1 earnings wrap up in the automation software sector, Pegasystems (NASDAQ:PEGA) posted a disappointing 9.6% revenue decline to $430 million, missing analyst estimates by 7.3%. Its stock dropped 11.8% post-report. Conversely, Appian (NASDAQ:APPN) showed robust growth with a 21.5% revenue increase to $202.2 million, beating expectations by 5.6%, yet its shares fell 9.2%. The sector overall saw revenues exceed consensus by 0.8%, but stocks fell 6.5% on average after earnings. Pegasystems' approach centers on AI-driven workflow automation, while Appian offers a low-code platform for complex processes. These contrasting performances highlight varied market reactions despite solid fundamental advances in automation software driven by AI and machine learning integration.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy
Previous Story

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Next Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

Go toTop